LuciaMasarovaMD

PubMed

• Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety.
  Lucia Masarova, John Mascarenhas, Raajit Rampal, Wilson Hu, Robert A Livingston
  Cancer. 2024-12-01
• Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
  Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, Yesid Alvarado, Gautam Borthakur
  Cancer. 2024-11-25
• Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
  Warren Fiskus, Christopher P Mill, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju
  Blood. 2024-11-19

Abstracts/Posters

• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Lucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
  Lucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
  Lucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
  Lucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
  Lucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Lucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Lucia Masarova, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Cytogenetic Stratifications in Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic Impact of Activating Mutations of the NRAS/KRAS Genes in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all